| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Diseases, Alcoholic | 51 | 2026 | 92 | 15.790 |
Why?
|
| Ethanol | 72 | 2026 | 330 | 15.660 |
Why?
|
| Hepatitis, Alcoholic | 38 | 2026 | 80 | 14.300 |
Why?
|
| Liver | 61 | 2026 | 879 | 9.380 |
Why?
|
| MicroRNAs | 36 | 2021 | 707 | 8.860 |
Why?
|
| Hepatocytes | 31 | 2025 | 225 | 7.020 |
Why?
|
| Hepacivirus | 32 | 2017 | 139 | 6.880 |
Why?
|
| Inflammasomes | 24 | 2025 | 342 | 6.770 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 19 | 2023 | 92 | 6.490 |
Why?
|
| Monocytes | 31 | 2024 | 364 | 5.930 |
Why?
|
| Fatty Liver | 19 | 2024 | 110 | 5.530 |
Why?
|
| Liver Diseases | 19 | 2024 | 160 | 5.170 |
Why?
|
| Fatty Liver, Alcoholic | 18 | 2020 | 33 | 4.970 |
Why?
|
| Alcohol Drinking | 26 | 2026 | 321 | 4.840 |
Why?
|
| Inflammation | 41 | 2025 | 1186 | 4.690 |
Why?
|
| Mice, Inbred C57BL | 57 | 2026 | 3471 | 4.520 |
Why?
|
| Hepatitis C, Chronic | 21 | 2017 | 91 | 4.450 |
Why?
|
| Macrophages | 22 | 2024 | 1058 | 4.310 |
Why?
|
| Extracellular Traps | 7 | 2025 | 45 | 4.300 |
Why?
|
| Hepatitis C | 22 | 2015 | 153 | 4.050 |
Why?
|
| Toll-Like Receptor 4 | 28 | 2024 | 351 | 3.900 |
Why?
|
| Exosomes | 10 | 2021 | 53 | 3.830 |
Why?
|
| Liver Cirrhosis | 16 | 2024 | 182 | 3.800 |
Why?
|
| Animals | 137 | 2026 | 21497 | 3.790 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 13 | 2025 | 260 | 3.670 |
Why?
|
| Mice | 78 | 2026 | 11193 | 3.390 |
Why?
|
| Acute-On-Chronic Liver Failure | 8 | 2025 | 8 | 3.250 |
Why?
|
| Lipopolysaccharides | 34 | 2024 | 627 | 3.220 |
Why?
|
| Chemical and Drug Induced Liver Injury | 9 | 2017 | 53 | 3.220 |
Why?
|
| Hepatitis | 10 | 2023 | 58 | 3.210 |
Why?
|
| Dendritic Cells | 20 | 2013 | 534 | 3.160 |
Why?
|
| Neutrophil Infiltration | 6 | 2025 | 62 | 3.140 |
Why?
|
| Interferon Regulatory Factor-3 | 6 | 2024 | 97 | 3.070 |
Why?
|
| Signal Transduction | 35 | 2024 | 3152 | 3.070 |
Why?
|
| Binge Drinking | 7 | 2025 | 38 | 3.050 |
Why?
|
| Liver Neoplasms | 14 | 2018 | 311 | 2.870 |
Why?
|
| Alcoholism | 19 | 2025 | 328 | 2.770 |
Why?
|
| Carcinoma, Hepatocellular | 11 | 2018 | 184 | 2.640 |
Why?
|
| Neutrophils | 7 | 2025 | 384 | 2.570 |
Why?
|
| Immunity, Innate | 19 | 2015 | 816 | 2.500 |
Why?
|
| Humans | 191 | 2026 | 65571 | 2.390 |
Why?
|
| Cytokines | 29 | 2020 | 958 | 2.380 |
Why?
|
| Interleukin-1beta | 13 | 2024 | 271 | 2.200 |
Why?
|
| Tumor Necrosis Factor-alpha | 25 | 2016 | 624 | 2.200 |
Why?
|
| Extracellular Vesicles | 4 | 2021 | 48 | 2.170 |
Why?
|
| Central Nervous System Depressants | 9 | 2025 | 46 | 2.150 |
Why?
|
| End Stage Liver Disease | 6 | 2023 | 34 | 2.090 |
Why?
|
| Inflammation Mediators | 12 | 2020 | 180 | 2.060 |
Why?
|
| Disease Models, Animal | 25 | 2024 | 2276 | 1.960 |
Why?
|
| NF-kappa B | 18 | 2022 | 475 | 1.900 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 8 | 2024 | 30 | 1.890 |
Why?
|
| Toll-Like Receptors | 14 | 2013 | 435 | 1.870 |
Why?
|
| Mice, Knockout | 25 | 2026 | 2158 | 1.860 |
Why?
|
| Endoplasmic Reticulum Stress | 3 | 2026 | 51 | 1.820 |
Why?
|
| Disease Progression | 17 | 2025 | 1214 | 1.750 |
Why?
|
| Gene Expression Regulation | 12 | 2024 | 1634 | 1.740 |
Why?
|
| Cholestasis | 4 | 2024 | 66 | 1.680 |
Why?
|
| Biomarkers | 18 | 2025 | 1471 | 1.680 |
Why?
|
| Female | 90 | 2026 | 34144 | 1.650 |
Why?
|
| Nucleotidyltransferases | 2 | 2026 | 68 | 1.640 |
Why?
|
| Macrophage Activation | 8 | 2019 | 119 | 1.630 |
Why?
|
| Toll-Like Receptor 2 | 15 | 2010 | 223 | 1.610 |
Why?
|
| Interferon-alpha | 10 | 2013 | 103 | 1.600 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 5 | 2023 | 37 | 1.570 |
Why?
|
| Carrier Proteins | 8 | 2019 | 719 | 1.540 |
Why?
|
| Kupffer Cells | 13 | 2019 | 43 | 1.540 |
Why?
|
| Microglia | 3 | 2024 | 253 | 1.530 |
Why?
|
| CARD Signaling Adaptor Proteins | 5 | 2025 | 70 | 1.470 |
Why?
|
| Immune System | 6 | 2015 | 133 | 1.420 |
Why?
|
| Viral Core Proteins | 8 | 2008 | 30 | 1.400 |
Why?
|
| Gastrointestinal Tract | 4 | 2025 | 189 | 1.400 |
Why?
|
| Interleukin-10 | 9 | 2015 | 164 | 1.390 |
Why?
|
| RNA, Viral | 6 | 2021 | 273 | 1.350 |
Why?
|
| Receptors, CCR2 | 3 | 2020 | 13 | 1.340 |
Why?
|
| Male | 61 | 2026 | 31089 | 1.320 |
Why?
|
| Up-Regulation | 12 | 2016 | 379 | 1.260 |
Why?
|
| Gastrointestinal Microbiome | 6 | 2023 | 259 | 1.250 |
Why?
|
| Cell Communication | 8 | 2024 | 135 | 1.250 |
Why?
|
| Myeloid Differentiation Factor 88 | 5 | 2014 | 204 | 1.240 |
Why?
|
| Myeloid Cells | 6 | 2012 | 97 | 1.220 |
Why?
|
| Interleukin-1 | 5 | 2017 | 156 | 1.200 |
Why?
|
| Liver Cirrhosis, Alcoholic | 6 | 2023 | 19 | 1.190 |
Why?
|
| Endotoxins | 5 | 2016 | 83 | 1.180 |
Why?
|
| Interferon-gamma | 8 | 2016 | 578 | 1.160 |
Why?
|
| Acetaminophen | 5 | 2017 | 57 | 1.160 |
Why?
|
| Membrane Glycoproteins | 5 | 2019 | 671 | 1.160 |
Why?
|
| Virus Replication | 8 | 2015 | 325 | 1.160 |
Why?
|
| Brain | 5 | 2020 | 1606 | 1.120 |
Why?
|
| Lipid Metabolism | 7 | 2021 | 228 | 1.110 |
Why?
|
| Syk Kinase | 3 | 2016 | 9 | 1.090 |
Why?
|
| Cells, Cultured | 17 | 2024 | 2208 | 1.090 |
Why?
|
| Alzheimer Disease | 2 | 2025 | 769 | 1.060 |
Why?
|
| Liver Neoplasms, Experimental | 3 | 2016 | 34 | 1.060 |
Why?
|
| Diet, High-Fat | 5 | 2024 | 181 | 1.050 |
Why?
|
| Interferon Type I | 5 | 2013 | 194 | 1.040 |
Why?
|
| Bile Acids and Salts | 2 | 2024 | 24 | 1.030 |
Why?
|
| Receptor-Interacting Protein Serine-Threonine Kinases | 4 | 2024 | 83 | 1.020 |
Why?
|
| Autophagy | 2 | 2019 | 236 | 1.000 |
Why?
|
| HSP90 Heat-Shock Proteins | 3 | 2018 | 65 | 0.990 |
Why?
|
| Leukocytes, Mononuclear | 6 | 2015 | 247 | 0.990 |
Why?
|
| Oxazines | 2 | 2016 | 13 | 0.980 |
Why?
|
| Cell Differentiation | 9 | 2017 | 1392 | 0.960 |
Why?
|
| Apoptosis | 11 | 2026 | 1104 | 0.950 |
Why?
|
| Gastroenterology | 2 | 2021 | 42 | 0.950 |
Why?
|
| Membrane Proteins | 4 | 2016 | 928 | 0.930 |
Why?
|
| Reactive Oxygen Species | 7 | 2025 | 242 | 0.920 |
Why?
|
| Pyridines | 2 | 2016 | 117 | 0.920 |
Why?
|
| Viral Nonstructural Proteins | 5 | 2007 | 94 | 0.910 |
Why?
|
| Phosphorylation | 9 | 2024 | 975 | 0.910 |
Why?
|
| Hepatic Stellate Cells | 2 | 2024 | 25 | 0.910 |
Why?
|
| Case-Control Studies | 12 | 2025 | 1156 | 0.900 |
Why?
|
| Uric Acid | 2 | 2015 | 48 | 0.900 |
Why?
|
| Immunity | 3 | 2020 | 109 | 0.890 |
Why?
|
| Liver Regeneration | 2 | 2017 | 20 | 0.890 |
Why?
|
| Research | 4 | 2021 | 200 | 0.860 |
Why?
|
| Killer Cells, Natural | 6 | 2015 | 220 | 0.850 |
Why?
|
| Methionine | 7 | 2015 | 57 | 0.850 |
Why?
|
| Caspase 1 | 5 | 2023 | 112 | 0.830 |
Why?
|
| Liver Cirrhosis, Experimental | 2 | 2016 | 6 | 0.820 |
Why?
|
| Liver Cirrhosis, Biliary | 1 | 2023 | 6 | 0.820 |
Why?
|
| Interleukin-13 | 1 | 2023 | 38 | 0.820 |
Why?
|
| Receptors, Cell Surface | 5 | 2015 | 431 | 0.820 |
Why?
|
| Cholangitis, Sclerosing | 1 | 2023 | 16 | 0.810 |
Why?
|
| Adenosine Triphosphate | 2 | 2015 | 299 | 0.800 |
Why?
|
| Hypoxia-Inducible Factor 1 | 2 | 2014 | 9 | 0.800 |
Why?
|
| Transcription Factors | 6 | 2017 | 1559 | 0.800 |
Why?
|
| Adult | 37 | 2026 | 17437 | 0.780 |
Why?
|
| Toll-Like Receptor 7 | 2 | 2017 | 104 | 0.780 |
Why?
|
| RNA, Messenger | 13 | 2022 | 1579 | 0.770 |
Why?
|
| CCR5 Receptor Antagonists | 2 | 2020 | 17 | 0.760 |
Why?
|
| Cell Proliferation | 6 | 2022 | 1043 | 0.750 |
Why?
|
| Cell Death | 4 | 2026 | 290 | 0.750 |
Why?
|
| Middle Aged | 38 | 2026 | 18286 | 0.750 |
Why?
|
| Pentoxifylline | 1 | 2022 | 8 | 0.750 |
Why?
|
| Choline Deficiency | 6 | 2014 | 14 | 0.750 |
Why?
|
| Antigens, CD | 2 | 2024 | 351 | 0.740 |
Why?
|
| Clinical Trials as Topic | 4 | 2025 | 466 | 0.740 |
Why?
|
| Alanine Transaminase | 7 | 2016 | 45 | 0.740 |
Why?
|
| DNA-Binding Proteins | 4 | 2017 | 1215 | 0.730 |
Why?
|
| Blotting, Western | 9 | 2017 | 621 | 0.730 |
Why?
|
| Research Design | 4 | 2025 | 584 | 0.730 |
Why?
|
| Cytoskeletal Proteins | 2 | 2013 | 206 | 0.730 |
Why?
|
| Intestines | 4 | 2018 | 172 | 0.710 |
Why?
|
| Acute-Phase Proteins | 2 | 2019 | 36 | 0.700 |
Why?
|
| Hepatitis, Chronic | 1 | 2021 | 6 | 0.700 |
Why?
|
| Chemokine CCL2 | 7 | 2016 | 60 | 0.690 |
Why?
|
| Real-Time Polymerase Chain Reaction | 7 | 2017 | 210 | 0.680 |
Why?
|
| Severity of Illness Index | 11 | 2025 | 1578 | 0.680 |
Why?
|
| Alcohols | 2 | 2014 | 13 | 0.680 |
Why?
|
| Craving | 1 | 2020 | 38 | 0.650 |
Why?
|
| Receptors, CCR5 | 1 | 2020 | 60 | 0.640 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 8 | 2019 | 460 | 0.640 |
Why?
|
| Multiple Organ Failure | 1 | 2020 | 47 | 0.630 |
Why?
|
| Sarcopenia | 1 | 2020 | 28 | 0.630 |
Why?
|
| Phagocytosis | 2 | 2018 | 266 | 0.620 |
Why?
|
| Diet | 5 | 2024 | 538 | 0.610 |
Why?
|
| Age Factors | 1 | 2023 | 1594 | 0.610 |
Why?
|
| Sepsis | 3 | 2018 | 293 | 0.600 |
Why?
|
| Indenes | 3 | 2024 | 15 | 0.590 |
Why?
|
| Toll-Like Receptor 8 | 2 | 2017 | 50 | 0.590 |
Why?
|
| Sulfones | 3 | 2024 | 42 | 0.590 |
Why?
|
| Prognosis | 10 | 2024 | 1792 | 0.590 |
Why?
|
| Furans | 3 | 2024 | 33 | 0.590 |
Why?
|
| Elasticity Imaging Techniques | 1 | 2019 | 27 | 0.580 |
Why?
|
| Membrane Microdomains | 3 | 2013 | 50 | 0.580 |
Why?
|
| Receptor, Interferon alpha-beta | 2 | 2016 | 53 | 0.580 |
Why?
|
| Liver Transplantation | 8 | 2025 | 221 | 0.580 |
Why?
|
| Mycobiome | 1 | 2018 | 3 | 0.570 |
Why?
|
| Microbiota | 2 | 2018 | 164 | 0.570 |
Why?
|
| Lysosomes | 1 | 2019 | 169 | 0.570 |
Why?
|
| Encephalitis | 1 | 2018 | 38 | 0.560 |
Why?
|
| RNA-Binding Proteins | 3 | 2023 | 458 | 0.560 |
Why?
|
| Interleukin-6 | 7 | 2023 | 325 | 0.560 |
Why?
|
| Hepatitis C Antibodies | 3 | 2012 | 9 | 0.560 |
Why?
|
| T-Lymphocytes, Regulatory | 3 | 2012 | 222 | 0.560 |
Why?
|
| Time Factors | 10 | 2026 | 3782 | 0.550 |
Why?
|
| Sex Characteristics | 1 | 2020 | 211 | 0.550 |
Why?
|
| Vimentin | 2 | 2015 | 19 | 0.550 |
Why?
|
| Toll-Like Receptor 9 | 4 | 2014 | 212 | 0.540 |
Why?
|
| Sulfonamides | 3 | 2024 | 138 | 0.540 |
Why?
|
| T-Lymphocytes | 5 | 2008 | 1025 | 0.540 |
Why?
|
| RNA, Ribosomal, 16S | 2 | 2017 | 105 | 0.540 |
Why?
|
| Reperfusion Injury | 2 | 2015 | 57 | 0.530 |
Why?
|
| Granuloma | 2 | 2008 | 44 | 0.530 |
Why?
|
| STAT3 Transcription Factor | 2 | 2008 | 73 | 0.530 |
Why?
|
| Metabolome | 1 | 2017 | 36 | 0.520 |
Why?
|
| Gene Expression Profiling | 5 | 2025 | 798 | 0.520 |
Why?
|
| Gene Expression | 5 | 2017 | 862 | 0.510 |
Why?
|
| Hypoxia | 3 | 2023 | 120 | 0.510 |
Why?
|
| Histone Deacetylases | 1 | 2017 | 66 | 0.510 |
Why?
|
| RNA, Neoplasm | 1 | 2016 | 36 | 0.480 |
Why?
|
| Lipopolysaccharide Receptors | 6 | 2008 | 144 | 0.480 |
Why?
|
| Anti-Infective Agents, Local | 2 | 2013 | 30 | 0.480 |
Why?
|
| Neutralization Tests | 3 | 2014 | 128 | 0.480 |
Why?
|
| Antigen-Presenting Cells | 3 | 2008 | 180 | 0.480 |
Why?
|
| Cell Line | 8 | 2015 | 2071 | 0.470 |
Why?
|
| Intestinal Mucosa | 2 | 2014 | 244 | 0.470 |
Why?
|
| Probiotics | 2 | 2023 | 56 | 0.470 |
Why?
|
| Interleukins | 2 | 2012 | 82 | 0.470 |
Why?
|
| Receptors, Interleukin-1 | 3 | 2022 | 66 | 0.470 |
Why?
|
| Probenecid | 1 | 2015 | 5 | 0.460 |
Why?
|
| Allopurinol | 1 | 2015 | 15 | 0.460 |
Why?
|
| Lymphocyte Antigen 96 | 3 | 2011 | 47 | 0.460 |
Why?
|
| Cell Polarity | 1 | 2015 | 111 | 0.450 |
Why?
|
| Adaptor Proteins, Signal Transducing | 4 | 2012 | 440 | 0.450 |
Why?
|
| NADPH Oxidases | 2 | 2012 | 70 | 0.440 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 6 | 2017 | 552 | 0.440 |
Why?
|
| Oxidative Stress | 6 | 2022 | 314 | 0.440 |
Why?
|
| RNA Stability | 2 | 2015 | 104 | 0.430 |
Why?
|
| Neoplasm Proteins | 1 | 2016 | 289 | 0.420 |
Why?
|
| Tetraspanin 28 | 2 | 2013 | 4 | 0.420 |
Why?
|
| Polymorphism, Genetic | 1 | 2014 | 197 | 0.420 |
Why?
|
| Immunocompromised Host | 1 | 2015 | 109 | 0.410 |
Why?
|
| Kidney | 4 | 2023 | 457 | 0.410 |
Why?
|
| Bacteria | 4 | 2022 | 336 | 0.410 |
Why?
|
| Immunity, Cellular | 3 | 2012 | 178 | 0.410 |
Why?
|
| Fibrosis | 3 | 2021 | 174 | 0.410 |
Why?
|
| Hepatitis B, Chronic | 1 | 2013 | 5 | 0.400 |
Why?
|
| Immune Tolerance | 2 | 2012 | 181 | 0.400 |
Why?
|
| Interleukin-12 | 2 | 2004 | 128 | 0.390 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2012 | 214 | 0.390 |
Why?
|
| Statistics, Nonparametric | 5 | 2014 | 215 | 0.390 |
Why?
|
| Tetraspanins | 1 | 2013 | 13 | 0.390 |
Why?
|
| Cyclin G1 | 1 | 2012 | 1 | 0.390 |
Why?
|
| Antibodies, Neutralizing | 1 | 2014 | 217 | 0.390 |
Why?
|
| Chronic Disease | 5 | 2024 | 769 | 0.380 |
Why?
|
| Microfilament Proteins | 1 | 2013 | 114 | 0.380 |
Why?
|
| Cerebellum | 1 | 2013 | 96 | 0.380 |
Why?
|
| DNA, Bacterial | 1 | 2014 | 270 | 0.380 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2016 | 591 | 0.380 |
Why?
|
| Sulfoxides | 2 | 2024 | 17 | 0.380 |
Why?
|
| Pancreatitis, Alcoholic | 2 | 2015 | 3 | 0.380 |
Why?
|
| Forkhead Transcription Factors | 1 | 2013 | 133 | 0.380 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2014 | 113 | 0.380 |
Why?
|
| Heterocyclic Compounds, 4 or More Rings | 2 | 2024 | 23 | 0.380 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2013 | 182 | 0.370 |
Why?
|
| Bone Marrow Cells | 2 | 2014 | 238 | 0.370 |
Why?
|
| Acute Kidney Injury | 2 | 2024 | 143 | 0.370 |
Why?
|
| Interleukin-1 Receptor-Associated Kinases | 2 | 2009 | 34 | 0.360 |
Why?
|
| Autoantigens | 1 | 2013 | 139 | 0.360 |
Why?
|
| Risk Factors | 11 | 2026 | 5436 | 0.360 |
Why?
|
| Cell Line, Tumor | 6 | 2013 | 1608 | 0.350 |
Why?
|
| Metagenome | 1 | 2011 | 18 | 0.350 |
Why?
|
| Poly I-C | 1 | 2011 | 76 | 0.340 |
Why?
|
| Triglycerides | 4 | 2014 | 250 | 0.340 |
Why?
|
| alpha-Fetoproteins | 2 | 2023 | 15 | 0.330 |
Why?
|
| National Institute on Alcohol Abuse and Alcoholism (U.S.) | 1 | 2010 | 1 | 0.330 |
Why?
|
| RNA, Double-Stranded | 1 | 2011 | 111 | 0.330 |
Why?
|
| Phenotype | 4 | 2016 | 1240 | 0.330 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2012 | 336 | 0.330 |
Why?
|
| Receptors, Immunologic | 3 | 2007 | 179 | 0.330 |
Why?
|
| Down-Regulation | 4 | 2018 | 328 | 0.320 |
Why?
|
| Toll-Like Receptor 1 | 2 | 2007 | 22 | 0.320 |
Why?
|
| Fatty Acids | 1 | 2011 | 205 | 0.320 |
Why?
|
| Electrophoretic Mobility Shift Assay | 4 | 2014 | 65 | 0.320 |
Why?
|
| Ligands | 5 | 2012 | 421 | 0.310 |
Why?
|
| Peroxisome Proliferator-Activated Receptors | 4 | 2022 | 7 | 0.310 |
Why?
|
| Antibody Formation | 2 | 2006 | 114 | 0.310 |
Why?
|
| Transcription Factor RelA | 2 | 2007 | 50 | 0.310 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2024 | 196 | 0.310 |
Why?
|
| Antiviral Agents | 5 | 2012 | 330 | 0.300 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 2 | 2007 | 152 | 0.300 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2013 | 647 | 0.300 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2013 | 742 | 0.300 |
Why?
|
| Gene Silencing | 1 | 2012 | 421 | 0.300 |
Why?
|
| Propionibacterium acnes | 2 | 2008 | 6 | 0.290 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 4 | 2015 | 350 | 0.290 |
Why?
|
| Transcriptome | 3 | 2025 | 407 | 0.290 |
Why?
|
| Suppressor of Cytokine Signaling Proteins | 1 | 2008 | 14 | 0.290 |
Why?
|
| CHO Cells | 5 | 2007 | 189 | 0.280 |
Why?
|
| Sex Factors | 3 | 2018 | 994 | 0.280 |
Why?
|
| Science | 1 | 2009 | 34 | 0.280 |
Why?
|
| STAT1 Transcription Factor | 1 | 2008 | 36 | 0.280 |
Why?
|
| Cricetinae | 5 | 2007 | 370 | 0.280 |
Why?
|
| RNA Virus Infections | 1 | 2008 | 4 | 0.280 |
Why?
|
| DNA Virus Infections | 1 | 2008 | 9 | 0.280 |
Why?
|
| Healthy Volunteers | 2 | 2020 | 73 | 0.270 |
Why?
|
| Cause of Death | 2 | 2019 | 223 | 0.270 |
Why?
|
| Leptin | 2 | 2005 | 89 | 0.270 |
Why?
|
| Toll-Like Receptor 6 | 1 | 2007 | 13 | 0.270 |
Why?
|
| ROC Curve | 3 | 2019 | 294 | 0.270 |
Why?
|
| Sp1 Transcription Factor | 1 | 2007 | 21 | 0.260 |
Why?
|
| Prednisone | 2 | 2024 | 86 | 0.260 |
Why?
|
| I-kappa B Kinase | 1 | 2007 | 50 | 0.260 |
Why?
|
| Transcription Factor AP-1 | 1 | 2007 | 46 | 0.260 |
Why?
|
| Autoimmunity | 1 | 2009 | 247 | 0.260 |
Why?
|
| src-Family Kinases | 1 | 2007 | 64 | 0.260 |
Why?
|
| Liver Function Tests | 4 | 2019 | 40 | 0.260 |
Why?
|
| Metabolic Syndrome | 2 | 2020 | 147 | 0.250 |
Why?
|
| Isoantigens | 2 | 2004 | 72 | 0.250 |
Why?
|
| Heme Oxygenase-1 | 1 | 2006 | 20 | 0.250 |
Why?
|
| Cell Culture Techniques | 1 | 2008 | 193 | 0.250 |
Why?
|
| Carbon Tetrachloride | 2 | 2016 | 11 | 0.250 |
Why?
|
| Systemic Inflammatory Response Syndrome | 2 | 2006 | 43 | 0.250 |
Why?
|
| Gene Knockdown Techniques | 2 | 2017 | 207 | 0.250 |
Why?
|
| Interferons | 3 | 2012 | 73 | 0.250 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 2 | 2004 | 152 | 0.240 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2008 | 247 | 0.240 |
Why?
|
| Biopsy | 4 | 2019 | 457 | 0.240 |
Why?
|
| Receptors, Pattern Recognition | 1 | 2006 | 36 | 0.240 |
Why?
|
| Forecasting | 2 | 2022 | 232 | 0.240 |
Why?
|
| HMGB1 Protein | 2 | 2018 | 26 | 0.240 |
Why?
|
| Complement System Proteins | 2 | 2024 | 107 | 0.240 |
Why?
|
| Receptors, Glucocorticoid | 2 | 2002 | 28 | 0.240 |
Why?
|
| Actins | 3 | 2014 | 262 | 0.240 |
Why?
|
| I-kappa B Proteins | 2 | 2002 | 39 | 0.240 |
Why?
|
| NF-kappa B p50 Subunit | 2 | 2022 | 24 | 0.240 |
Why?
|
| Propionibacterium | 1 | 2005 | 5 | 0.240 |
Why?
|
| Homeostasis | 2 | 2023 | 374 | 0.230 |
Why?
|
| Interleukin-1alpha | 2 | 2017 | 25 | 0.230 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2005 | 30 | 0.230 |
Why?
|
| Protein Binding | 4 | 2015 | 1649 | 0.230 |
Why?
|
| Child of Impaired Parents | 1 | 2025 | 23 | 0.230 |
Why?
|
| Zinc | 2 | 2024 | 94 | 0.230 |
Why?
|
| Immunohistochemistry | 3 | 2017 | 905 | 0.220 |
Why?
|
| Models, Biological | 4 | 2015 | 1216 | 0.220 |
Why?
|
| Mitochondria | 2 | 2005 | 403 | 0.220 |
Why?
|
| Adjuvants, Immunologic | 1 | 2006 | 236 | 0.220 |
Why?
|
| B-Lymphocytes | 1 | 2008 | 577 | 0.220 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2006 | 205 | 0.220 |
Why?
|
| MAP Kinase Signaling System | 3 | 2015 | 235 | 0.220 |
Why?
|
| Clonal Anergy | 1 | 2004 | 23 | 0.220 |
Why?
|
| United States | 8 | 2025 | 8135 | 0.220 |
Why?
|
| Antigens, Ly | 1 | 2004 | 44 | 0.220 |
Why?
|
| Granulocytes | 1 | 2024 | 73 | 0.210 |
Why?
|
| Primary Cell Culture | 2 | 2015 | 79 | 0.210 |
Why?
|
| Antigen Presentation | 2 | 2004 | 242 | 0.210 |
Why?
|
| HIV Infections | 1 | 2011 | 965 | 0.210 |
Why?
|
| Viral Proteins | 3 | 2013 | 270 | 0.210 |
Why?
|
| Lipocalin-2 | 1 | 2023 | 9 | 0.210 |
Why?
|
| Amino Acids, Aromatic | 1 | 2023 | 7 | 0.210 |
Why?
|
| Bile Ducts | 1 | 2023 | 26 | 0.200 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2023 | 23 | 0.200 |
Why?
|
| Immunoprecipitation | 2 | 2014 | 130 | 0.200 |
Why?
|
| Growth Inhibitors | 1 | 2003 | 25 | 0.200 |
Why?
|
| Proportional Hazards Models | 3 | 2025 | 742 | 0.200 |
Why?
|
| Proteomics | 2 | 2024 | 306 | 0.200 |
Why?
|
| Cholesterol | 3 | 2021 | 261 | 0.200 |
Why?
|
| Feeding Behavior | 2 | 2015 | 264 | 0.200 |
Why?
|
| Recombinant Proteins | 6 | 2012 | 712 | 0.200 |
Why?
|
| Nuclear Proteins | 3 | 2016 | 794 | 0.200 |
Why?
|
| Amyloid beta-Peptides | 1 | 2025 | 320 | 0.200 |
Why?
|
| Cytochrome P-450 CYP2E1 | 2 | 2016 | 15 | 0.200 |
Why?
|
| Polyethylene Glycols | 4 | 2012 | 174 | 0.200 |
Why?
|
| Permeability | 2 | 2014 | 50 | 0.200 |
Why?
|
| Physicians | 1 | 2009 | 489 | 0.190 |
Why?
|
| Coculture Techniques | 2 | 2013 | 103 | 0.190 |
Why?
|
| Mice, Transgenic | 2 | 2025 | 1310 | 0.190 |
Why?
|
| Transforming Growth Factor beta | 3 | 2015 | 181 | 0.190 |
Why?
|
| Interleukin-2 | 1 | 2003 | 167 | 0.190 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 2 | 2016 | 78 | 0.190 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2002 | 64 | 0.190 |
Why?
|
| Coenzyme A Ligases | 1 | 2022 | 13 | 0.190 |
Why?
|
| Flow Cytometry | 4 | 2012 | 677 | 0.190 |
Why?
|
| Energy Metabolism | 1 | 2005 | 395 | 0.190 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2022 | 41 | 0.190 |
Why?
|
| Ki-67 Antigen | 1 | 2022 | 38 | 0.190 |
Why?
|
| Receptors, IgG | 1 | 2002 | 41 | 0.190 |
Why?
|
| Methylprednisolone | 1 | 2022 | 38 | 0.190 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2022 | 41 | 0.180 |
Why?
|
| Chemical and Drug Induced Liver Injury, Chronic | 1 | 2022 | 3 | 0.180 |
Why?
|
| Immunosuppressive Agents | 1 | 2004 | 384 | 0.180 |
Why?
|
| Methylamines | 1 | 2022 | 11 | 0.180 |
Why?
|
| Apoptosis Regulatory Proteins | 2 | 2013 | 154 | 0.180 |
Why?
|
| Collagen Type I | 2 | 2014 | 43 | 0.180 |
Why?
|
| Cell Nucleus | 3 | 2015 | 639 | 0.180 |
Why?
|
| Hyperglycemia | 1 | 2022 | 105 | 0.180 |
Why?
|
| Dietary Sugars | 1 | 2021 | 9 | 0.180 |
Why?
|
| Anti-Bacterial Agents | 2 | 2018 | 822 | 0.170 |
Why?
|
| Pyroptosis | 1 | 2021 | 36 | 0.170 |
Why?
|
| Nucleoside-Triphosphatase | 3 | 2007 | 40 | 0.170 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2008 | 881 | 0.170 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2012 | 302 | 0.170 |
Why?
|
| Host-Pathogen Interactions | 2 | 2014 | 282 | 0.170 |
Why?
|
| Aged | 9 | 2025 | 14951 | 0.170 |
Why?
|
| Blood Alcohol Content | 1 | 2020 | 2 | 0.170 |
Why?
|
| Insulin | 2 | 2015 | 692 | 0.170 |
Why?
|
| Survival Analysis | 2 | 2019 | 591 | 0.170 |
Why?
|
| Parents | 1 | 2025 | 410 | 0.170 |
Why?
|
| Response Elements | 2 | 2016 | 45 | 0.170 |
Why?
|
| Lymphocyte Culture Test, Mixed | 2 | 2012 | 35 | 0.170 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2022 | 184 | 0.160 |
Why?
|
| Interferon Regulatory Factor-7 | 2 | 2010 | 33 | 0.160 |
Why?
|
| Serine Endopeptidases | 3 | 2007 | 124 | 0.160 |
Why?
|
| Imidazoles | 1 | 2020 | 86 | 0.160 |
Why?
|
| DEAD-box RNA Helicases | 3 | 2007 | 131 | 0.160 |
Why?
|
| para-Aminobenzoates | 1 | 2020 | 2 | 0.160 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2019 | 427 | 0.160 |
Why?
|
| Protein Kinases | 1 | 2021 | 153 | 0.160 |
Why?
|
| Matrix Metalloproteinase 2 | 2 | 2011 | 29 | 0.160 |
Why?
|
| Enzyme Inhibitors | 2 | 2015 | 375 | 0.160 |
Why?
|
| Th2 Cells | 3 | 2017 | 98 | 0.160 |
Why?
|
| Lysosomal-Associated Membrane Protein 1 | 1 | 2019 | 9 | 0.150 |
Why?
|
| Dipeptides | 1 | 2020 | 68 | 0.150 |
Why?
|
| Lysosomal-Associated Membrane Protein 2 | 1 | 2019 | 14 | 0.150 |
Why?
|
| Length of Stay | 3 | 2020 | 832 | 0.150 |
Why?
|
| Palmitic Acid | 1 | 2019 | 15 | 0.150 |
Why?
|
| Mitochondria, Liver | 2 | 2011 | 13 | 0.150 |
Why?
|
| Virus Diseases | 2 | 2015 | 123 | 0.150 |
Why?
|
| Myocardium | 1 | 2021 | 298 | 0.150 |
Why?
|
| Fibroblasts | 2 | 2021 | 418 | 0.150 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2019 | 115 | 0.140 |
Why?
|
| Young Adult | 3 | 2020 | 4849 | 0.140 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2019 | 130 | 0.140 |
Why?
|
| Protein S | 1 | 2018 | 2 | 0.140 |
Why?
|
| Prospective Studies | 5 | 2026 | 3363 | 0.140 |
Why?
|
| Viral Envelope Proteins | 3 | 2012 | 103 | 0.140 |
Why?
|
| Treatment Outcome | 6 | 2024 | 5821 | 0.140 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2019 | 2250 | 0.140 |
Why?
|
| Self Report | 1 | 2020 | 393 | 0.140 |
Why?
|
| Life Style | 1 | 2020 | 320 | 0.140 |
Why?
|
| Fungi | 1 | 2018 | 62 | 0.140 |
Why?
|
| DNA | 2 | 2016 | 855 | 0.130 |
Why?
|
| Thiazoles | 2 | 2011 | 49 | 0.130 |
Why?
|
| Verrucomicrobia | 1 | 2017 | 3 | 0.130 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2018 | 83 | 0.130 |
Why?
|
| Hep G2 Cells | 2 | 2018 | 30 | 0.130 |
Why?
|
| RAW 264.7 Cells | 1 | 2017 | 55 | 0.130 |
Why?
|
| Academic Medical Centers | 1 | 2019 | 315 | 0.130 |
Why?
|
| Patient Care Management | 1 | 2017 | 30 | 0.130 |
Why?
|
| Cellular Microenvironment | 1 | 2017 | 23 | 0.130 |
Why?
|
| Disease Management | 1 | 2019 | 237 | 0.130 |
Why?
|
| Multivariate Analysis | 1 | 2019 | 936 | 0.130 |
Why?
|
| Drosophila Proteins | 1 | 2002 | 755 | 0.130 |
Why?
|
| Public Health | 1 | 2019 | 189 | 0.130 |
Why?
|
| RNA | 2 | 2012 | 432 | 0.120 |
Why?
|
| Antibodies, Monoclonal | 2 | 2012 | 876 | 0.120 |
Why?
|
| Perilipin-2 | 1 | 2016 | 1 | 0.120 |
Why?
|
| Diethylnitrosamine | 1 | 2016 | 2 | 0.120 |
Why?
|
| Cricetulus | 2 | 2007 | 100 | 0.120 |
Why?
|
| Mass Spectrometry | 1 | 2018 | 312 | 0.120 |
Why?
|
| Diethylamines | 1 | 2016 | 3 | 0.120 |
Why?
|
| Fatty Acid Synthases | 1 | 2016 | 24 | 0.120 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 1115 | 0.120 |
Why?
|
| Lung | 1 | 2021 | 969 | 0.120 |
Why?
|
| Mannose-Binding Lectins | 1 | 2015 | 21 | 0.120 |
Why?
|
| Sensitivity and Specificity | 1 | 2019 | 1174 | 0.120 |
Why?
|
| PPAR alpha | 1 | 2016 | 34 | 0.120 |
Why?
|
| Thrombosis | 1 | 2018 | 204 | 0.120 |
Why?
|
| RNA Transport | 1 | 2015 | 31 | 0.120 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2007 | 219 | 0.120 |
Why?
|
| Cardiovascular Diseases | 2 | 2022 | 866 | 0.120 |
Why?
|
| Antimetabolites | 1 | 2015 | 18 | 0.120 |
Why?
|
| Adjuvants, Pharmaceutic | 1 | 2015 | 7 | 0.120 |
Why?
|
| Lymphocyte Activation | 2 | 2008 | 761 | 0.120 |
Why?
|
| Interleukin-33 | 1 | 2015 | 19 | 0.120 |
Why?
|
| Choline | 1 | 2015 | 23 | 0.120 |
Why?
|
| Smad3 Protein | 1 | 2015 | 17 | 0.110 |
Why?
|
| CCAAT-Enhancer-Binding Protein-beta | 1 | 2015 | 22 | 0.110 |
Why?
|
| Extracellular Space | 1 | 2015 | 29 | 0.110 |
Why?
|
| Recovery of Function | 1 | 2017 | 290 | 0.110 |
Why?
|
| Culture Media, Conditioned | 1 | 2015 | 53 | 0.110 |
Why?
|
| RNA, Small Interfering | 2 | 2015 | 968 | 0.110 |
Why?
|
| Risk Assessment | 2 | 2019 | 2098 | 0.110 |
Why?
|
| Lectins, C-Type | 1 | 2015 | 91 | 0.110 |
Why?
|
| Interleukin-18 | 1 | 2015 | 75 | 0.110 |
Why?
|
| Dietary Carbohydrates | 1 | 2015 | 62 | 0.110 |
Why?
|
| Organ Size | 1 | 2015 | 173 | 0.110 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2022 | 721 | 0.110 |
Why?
|
| Terminology as Topic | 1 | 2016 | 145 | 0.110 |
Why?
|
| Mice, Mutant Strains | 2 | 2005 | 302 | 0.110 |
Why?
|
| Phosphatidylinositol-3,4,5-Trisphosphate 5-Phosphatases | 1 | 2014 | 3 | 0.110 |
Why?
|
| MAP Kinase Kinase Kinase 3 | 1 | 2014 | 3 | 0.110 |
Why?
|
| Pancreatitis-Associated Proteins | 1 | 2014 | 4 | 0.110 |
Why?
|
| Inositol Polyphosphate 5-Phosphatases | 1 | 2014 | 8 | 0.110 |
Why?
|
| Tissue Distribution | 1 | 2015 | 294 | 0.110 |
Why?
|
| Immunophenotyping | 1 | 2015 | 198 | 0.110 |
Why?
|
| Procollagen | 1 | 2014 | 11 | 0.110 |
Why?
|
| Microscopy, Confocal | 1 | 2015 | 245 | 0.110 |
Why?
|
| Bacterial Translocation | 1 | 2014 | 10 | 0.110 |
Why?
|
| Receptors, Virus | 1 | 2014 | 73 | 0.110 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2014 | 47 | 0.110 |
Why?
|
| Dietary Sucrose | 1 | 2014 | 24 | 0.110 |
Why?
|
| Adolescent | 5 | 2010 | 6401 | 0.110 |
Why?
|
| Fructose | 1 | 2014 | 37 | 0.100 |
Why?
|
| Gene Deletion | 1 | 2015 | 317 | 0.100 |
Why?
|
| Drug Delivery Systems | 1 | 2017 | 332 | 0.100 |
Why?
|
| Body Weight | 1 | 2015 | 380 | 0.100 |
Why?
|
| Head and Neck Neoplasms | 1 | 2015 | 168 | 0.100 |
Why?
|
| Bacterial Infections | 1 | 2015 | 156 | 0.100 |
Why?
|
| Weight Gain | 1 | 2014 | 169 | 0.100 |
Why?
|
| Nitric Oxide | 2 | 2005 | 178 | 0.100 |
Why?
|
| Argonaute Proteins | 1 | 2014 | 151 | 0.100 |
Why?
|
| Acetylation | 1 | 2013 | 123 | 0.100 |
Why?
|
| Receptors, Interferon | 1 | 2012 | 21 | 0.100 |
Why?
|
| Receptors, Interleukin-1 Type I | 1 | 2012 | 9 | 0.100 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2013 | 135 | 0.100 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 2012 | 49 | 0.100 |
Why?
|
| Biomarkers, Tumor | 1 | 2016 | 523 | 0.090 |
Why?
|
| Ribavirin | 1 | 2012 | 23 | 0.090 |
Why?
|
| NLR Proteins | 1 | 2012 | 11 | 0.090 |
Why?
|
| Regression Analysis | 1 | 2013 | 500 | 0.090 |
Why?
|
| Asia | 2 | 2025 | 28 | 0.090 |
Why?
|
| Microtubules | 1 | 2013 | 211 | 0.090 |
Why?
|
| Organ Dysfunction Scores | 2 | 2025 | 23 | 0.090 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2020 | 1686 | 0.090 |
Why?
|
| Aspartate Aminotransferases | 1 | 2012 | 35 | 0.090 |
Why?
|
| Genetic Markers | 1 | 2012 | 131 | 0.090 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2012 | 99 | 0.090 |
Why?
|
| Software | 1 | 2015 | 396 | 0.090 |
Why?
|
| Endocytosis | 1 | 2013 | 153 | 0.090 |
Why?
|
| Single-Cell Analysis | 2 | 2025 | 126 | 0.090 |
Why?
|
| DNA Primers | 1 | 2012 | 301 | 0.090 |
Why?
|
| Calcium-Binding Proteins | 1 | 2012 | 94 | 0.090 |
Why?
|
| Bone Morphogenetic Protein 2 | 1 | 2012 | 49 | 0.090 |
Why?
|
| Metals | 1 | 2012 | 65 | 0.090 |
Why?
|
| Activins | 1 | 2012 | 55 | 0.090 |
Why?
|
| Blood Glucose | 1 | 2014 | 490 | 0.090 |
Why?
|
| Bone Marrow Transplantation | 1 | 2012 | 140 | 0.090 |
Why?
|
| Fibroblast Growth Factors | 1 | 2012 | 76 | 0.090 |
Why?
|
| RNA Interference | 1 | 2015 | 642 | 0.090 |
Why?
|
| Endpoint Determination | 2 | 2025 | 27 | 0.090 |
Why?
|
| Quinolines | 1 | 2011 | 48 | 0.090 |
Why?
|
| CpG Islands | 1 | 2012 | 220 | 0.090 |
Why?
|
| Heart | 2 | 2021 | 295 | 0.090 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2011 | 8 | 0.090 |
Why?
|
| Hepatitis B | 1 | 2011 | 33 | 0.090 |
Why?
|
| Thiobarbituric Acid Reactive Substances | 1 | 2011 | 16 | 0.090 |
Why?
|
| Disease | 1 | 2011 | 27 | 0.090 |
Why?
|
| Pancreatic Neoplasms | 1 | 2015 | 363 | 0.090 |
Why?
|
| Postoperative Complications | 2 | 2010 | 1331 | 0.090 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2011 | 94 | 0.080 |
Why?
|
| Molecular Biology | 1 | 2011 | 67 | 0.080 |
Why?
|
| Insulin Resistance | 1 | 2014 | 413 | 0.080 |
Why?
|
| Lipid Peroxidation | 1 | 2011 | 66 | 0.080 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2012 | 63 | 0.080 |
Why?
|
| Embryonic Stem Cells | 1 | 2012 | 159 | 0.080 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2011 | 61 | 0.080 |
Why?
|
| Analysis of Variance | 1 | 2012 | 612 | 0.080 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2012 | 149 | 0.080 |
Why?
|
| Dietary Fats | 1 | 2011 | 178 | 0.080 |
Why?
|
| Collagen | 1 | 2011 | 134 | 0.080 |
Why?
|
| Esophageal and Gastric Varices | 1 | 2010 | 15 | 0.080 |
Why?
|
| Comorbidity | 2 | 2011 | 1122 | 0.080 |
Why?
|
| Oxygen | 1 | 2012 | 326 | 0.080 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2011 | 142 | 0.080 |
Why?
|
| Models, Animal | 1 | 2011 | 243 | 0.080 |
Why?
|
| Elective Surgical Procedures | 1 | 2010 | 121 | 0.080 |
Why?
|
| Base Sequence | 1 | 2012 | 1346 | 0.080 |
Why?
|
| History, 21st Century | 1 | 2010 | 183 | 0.080 |
Why?
|
| Receptors, Cytokine | 1 | 2009 | 13 | 0.080 |
Why?
|
| Congresses as Topic | 2 | 2020 | 80 | 0.070 |
Why?
|
| History, 20th Century | 1 | 2010 | 241 | 0.070 |
Why?
|
| Invertebrates | 1 | 2009 | 20 | 0.070 |
Why?
|
| Behavior | 1 | 2009 | 36 | 0.070 |
Why?
|
| Primates | 1 | 2009 | 54 | 0.070 |
Why?
|
| Knowledge | 1 | 2009 | 31 | 0.070 |
Why?
|
| Vertebrates | 1 | 2009 | 45 | 0.070 |
Why?
|
| Genotype | 1 | 2011 | 678 | 0.070 |
Why?
|
| NADP | 1 | 2008 | 22 | 0.070 |
Why?
|
| Chimera | 1 | 2008 | 47 | 0.070 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2009 | 65 | 0.070 |
Why?
|
| Proteins | 1 | 2014 | 764 | 0.070 |
Why?
|
| Suppressor of Cytokine Signaling 1 Protein | 1 | 2008 | 5 | 0.070 |
Why?
|
| Suppressor of Cytokine Signaling 3 Protein | 1 | 2008 | 8 | 0.070 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2008 | 54 | 0.070 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2009 | 120 | 0.070 |
Why?
|
| Herbal Medicine | 1 | 2008 | 3 | 0.070 |
Why?
|
| Drug Therapy, Combination | 2 | 2024 | 473 | 0.070 |
Why?
|
| Hepatitis C Antigens | 1 | 2007 | 1 | 0.070 |
Why?
|
| Retrospective Studies | 1 | 2020 | 6899 | 0.070 |
Why?
|
| Cell Separation | 1 | 2008 | 149 | 0.070 |
Why?
|
| Asthma | 1 | 2012 | 473 | 0.070 |
Why?
|
| Mammals | 1 | 2009 | 223 | 0.070 |
Why?
|
| Career Choice | 1 | 2009 | 134 | 0.070 |
Why?
|
| Acute Disease | 1 | 2009 | 681 | 0.070 |
Why?
|
| Cell Movement | 2 | 2008 | 478 | 0.070 |
Why?
|
| Biomedical Research | 1 | 2010 | 274 | 0.070 |
Why?
|
| Macrophages, Peritoneal | 1 | 2007 | 77 | 0.060 |
Why?
|
| Luminescent Proteins | 1 | 2007 | 132 | 0.060 |
Why?
|
| Green Fluorescent Proteins | 1 | 2008 | 377 | 0.060 |
Why?
|
| Viruses | 1 | 2008 | 82 | 0.060 |
Why?
|
| Behavior, Animal | 1 | 2009 | 238 | 0.060 |
Why?
|
| Leukopenia | 1 | 2006 | 15 | 0.060 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2007 | 94 | 0.060 |
Why?
|
| Immunologic Factors | 1 | 2008 | 110 | 0.060 |
Why?
|
| Diagnosis, Differential | 1 | 2009 | 999 | 0.060 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2007 | 143 | 0.060 |
Why?
|
| Logistic Models | 2 | 2025 | 1281 | 0.060 |
Why?
|
| Viral Load | 2 | 2021 | 231 | 0.060 |
Why?
|
| Cushing Syndrome | 1 | 2006 | 10 | 0.060 |
Why?
|
| Ketoconazole | 1 | 2006 | 11 | 0.060 |
Why?
|
| Cytoskeleton | 1 | 2007 | 140 | 0.060 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 1 | 2006 | 81 | 0.060 |
Why?
|
| src Homology Domains | 1 | 2006 | 21 | 0.060 |
Why?
|
| Membrane Fluidity | 1 | 2006 | 15 | 0.060 |
Why?
|
| Pituitary-Adrenal System | 1 | 2006 | 60 | 0.060 |
Why?
|
| Cell Survival | 2 | 2012 | 602 | 0.060 |
Why?
|
| Cytoplasm | 1 | 2007 | 285 | 0.060 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2006 | 88 | 0.060 |
Why?
|
| Receptors, Scavenger | 1 | 2005 | 9 | 0.060 |
Why?
|
| Double-Blind Method | 2 | 2024 | 749 | 0.060 |
Why?
|
| Ischemic Preconditioning, Myocardial | 1 | 2005 | 23 | 0.060 |
Why?
|
| Enzyme Activation | 1 | 2006 | 389 | 0.060 |
Why?
|
| Liver Failure, Acute | 1 | 2005 | 26 | 0.060 |
Why?
|
| Heme Oxygenase (Decyclizing) | 1 | 2005 | 9 | 0.060 |
Why?
|
| Receptors, Leptin | 1 | 2005 | 13 | 0.060 |
Why?
|
| Antigens, Differentiation | 1 | 2005 | 142 | 0.060 |
Why?
|
| Nitric Oxide Synthase | 1 | 2005 | 49 | 0.060 |
Why?
|
| Antifungal Agents | 1 | 2006 | 136 | 0.060 |
Why?
|
| Dependovirus | 1 | 2012 | 744 | 0.060 |
Why?
|
| Mice, Obese | 1 | 2005 | 80 | 0.060 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2005 | 71 | 0.060 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2006 | 213 | 0.050 |
Why?
|
| Molecular Targeted Therapy | 1 | 2025 | 130 | 0.050 |
Why?
|
| Obesity | 2 | 2020 | 1266 | 0.050 |
Why?
|
| Atherosclerosis | 1 | 2006 | 157 | 0.050 |
Why?
|
| Stress, Physiological | 1 | 2006 | 209 | 0.050 |
Why?
|
| Hydroxylation | 1 | 2023 | 10 | 0.050 |
Why?
|
| Tryptophan | 1 | 2023 | 56 | 0.050 |
Why?
|
| Tyrosine | 1 | 2023 | 94 | 0.050 |
Why?
|
| Proline | 1 | 2023 | 49 | 0.050 |
Why?
|
| Pneumonia | 1 | 2006 | 292 | 0.050 |
Why?
|
| Proteome | 1 | 2024 | 160 | 0.050 |
Why?
|
| NF-KappaB Inhibitor alpha | 1 | 2002 | 27 | 0.050 |
Why?
|
| Coenzyme A | 1 | 2022 | 6 | 0.050 |
Why?
|
| Transfection | 1 | 2004 | 706 | 0.050 |
Why?
|
| Translocation, Genetic | 1 | 2002 | 74 | 0.050 |
Why?
|
| Carbon Monoxide | 1 | 2002 | 63 | 0.050 |
Why?
|
| Heat-Shock Proteins | 1 | 2002 | 69 | 0.050 |
Why?
|
| Thiazolidinediones | 1 | 2002 | 50 | 0.050 |
Why?
|
| Jurkat Cells | 1 | 2002 | 110 | 0.050 |
Why?
|
| Graft Rejection | 2 | 2018 | 302 | 0.050 |
Why?
|
| Heat-Shock Response | 1 | 2002 | 39 | 0.050 |
Why?
|
| Lipoprotein(a) | 1 | 2021 | 8 | 0.050 |
Why?
|
| Cross-Linking Reagents | 1 | 2002 | 118 | 0.050 |
Why?
|
| Apolipoproteins B | 1 | 2021 | 19 | 0.050 |
Why?
|
| Cell Division | 1 | 2003 | 457 | 0.040 |
Why?
|
| Liver Circulation | 1 | 2021 | 11 | 0.040 |
Why?
|
| Random Allocation | 1 | 2022 | 201 | 0.040 |
Why?
|
| Atlases as Topic | 1 | 2021 | 13 | 0.040 |
Why?
|
| Hemodynamics | 1 | 2002 | 253 | 0.040 |
Why?
|
| Lipoproteins | 1 | 2021 | 85 | 0.040 |
Why?
|
| Pulmonary Alveoli | 1 | 2021 | 43 | 0.040 |
Why?
|
| Autopsy | 1 | 2021 | 56 | 0.040 |
Why?
|
| Phagocytes | 1 | 2021 | 52 | 0.040 |
Why?
|
| Biological Specimen Banks | 1 | 2021 | 24 | 0.040 |
Why?
|
| Complement Factor D | 1 | 2020 | 4 | 0.040 |
Why?
|
| Complement C5 | 1 | 2020 | 8 | 0.040 |
Why?
|
| Complement C4 | 1 | 2020 | 12 | 0.040 |
Why?
|
| Complement C2 | 1 | 2020 | 9 | 0.040 |
Why?
|
| Complement Factor B | 1 | 2020 | 11 | 0.040 |
Why?
|
| Dexamethasone | 1 | 2002 | 210 | 0.040 |
Why?
|
| Public Opinion | 1 | 2020 | 25 | 0.040 |
Why?
|
| Organ Specificity | 1 | 2021 | 199 | 0.040 |
Why?
|
| Complement C3 | 1 | 2020 | 59 | 0.040 |
Why?
|
| Epigenesis, Genetic | 1 | 2024 | 405 | 0.040 |
Why?
|
| Incidence | 1 | 2024 | 1410 | 0.040 |
Why?
|
| Cohort Studies | 1 | 2006 | 2643 | 0.040 |
Why?
|
| Attitude | 1 | 2020 | 101 | 0.040 |
Why?
|
| Nutrition Therapy | 1 | 2020 | 9 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2020 | 153 | 0.040 |
Why?
|
| Hypoglycemic Agents | 1 | 2002 | 223 | 0.040 |
Why?
|
| Regeneration | 1 | 2021 | 122 | 0.040 |
Why?
|
| Endothelial Cells | 1 | 2021 | 198 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2023 | 1025 | 0.040 |
Why?
|
| Glucose | 1 | 2022 | 478 | 0.040 |
Why?
|
| Genome-Wide Association Study | 1 | 2021 | 369 | 0.040 |
Why?
|
| Global Burden of Disease | 1 | 2018 | 13 | 0.040 |
Why?
|
| North America | 1 | 2018 | 114 | 0.040 |
Why?
|
| Epithelial Cells | 1 | 2021 | 417 | 0.040 |
Why?
|
| Behavior Therapy | 1 | 2020 | 168 | 0.040 |
Why?
|
| Cell Membrane | 1 | 2021 | 510 | 0.030 |
Why?
|
| Europe | 1 | 2018 | 201 | 0.030 |
Why?
|
| Recurrence | 1 | 2020 | 659 | 0.030 |
Why?
|
| Amino Acid Sequence | 2 | 2012 | 1619 | 0.030 |
Why?
|
| Needs Assessment | 1 | 2019 | 204 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2017 | 237 | 0.030 |
Why?
|
| Feces | 1 | 2017 | 117 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2020 | 796 | 0.030 |
Why?
|
| Consensus Development Conferences, NIH as Topic | 1 | 2016 | 2 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2020 | 888 | 0.030 |
Why?
|
| Th1 Cells | 2 | 2006 | 173 | 0.030 |
Why?
|
| Pan troglodytes | 1 | 2012 | 33 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2020 | 2793 | 0.020 |
Why?
|
| Acyl-CoA Oxidase | 1 | 2011 | 7 | 0.020 |
Why?
|
| Carnitine O-Palmitoyltransferase | 1 | 2011 | 7 | 0.020 |
Why?
|
| Systems Biology | 1 | 2011 | 36 | 0.020 |
Why?
|
| Drug Combinations | 1 | 2012 | 171 | 0.020 |
Why?
|
| Metabolomics | 1 | 2011 | 60 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2021 | 5617 | 0.020 |
Why?
|
| Quality of Life | 1 | 2018 | 1277 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2012 | 523 | 0.020 |
Why?
|
| Epitopes, B-Lymphocyte | 1 | 2009 | 18 | 0.020 |
Why?
|
| Epitope Mapping | 1 | 2009 | 52 | 0.020 |
Why?
|
| Conserved Sequence | 1 | 2009 | 175 | 0.020 |
Why?
|
| Medication Adherence | 1 | 2010 | 199 | 0.020 |
Why?
|
| Genomics | 1 | 2011 | 394 | 0.020 |
Why?
|
| Silymarin | 1 | 2008 | 3 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2012 | 2517 | 0.020 |
Why?
|
| Digestive System Neoplasms | 1 | 2006 | 3 | 0.020 |
Why?
|
| APACHE | 1 | 2006 | 43 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2009 | 2017 | 0.010 |
Why?
|
| Morphine | 1 | 2006 | 62 | 0.010 |
Why?
|
| Gastrointestinal Diseases | 1 | 2006 | 72 | 0.010 |
Why?
|
| Interviews as Topic | 1 | 2008 | 534 | 0.010 |
Why?
|
| Patient Selection | 1 | 2008 | 488 | 0.010 |
Why?
|
| Hydrocortisone | 1 | 2006 | 194 | 0.010 |
Why?
|
| Lung Diseases | 1 | 2006 | 183 | 0.010 |
Why?
|
| Mutation | 1 | 2012 | 2679 | 0.010 |
Why?
|
| Chromans | 1 | 2002 | 16 | 0.010 |
Why?
|
| Transaminases | 1 | 2002 | 15 | 0.010 |
Why?
|
| Alkaline Phosphatase | 1 | 2002 | 47 | 0.010 |
Why?
|
| Neoplasms | 1 | 2006 | 1413 | 0.010 |
Why?
|